Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 17/20 | 0.62 |
| ▸ | ATF1 | P18846 | 12/20 | 0.62 |
| ▸ | XPO1 | O14980 | 5/20 | 0.61 |
| ▸ | JUN | P05412 | 6/20 | 0.59 |
| ▸ | NFKB2 | Q00653 | 6/20 | 0.59 |
| ▸ | RELA | Q04206 | 6/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL480176 | 0.84 | XPO1 (0.62) | NFKB1ATF1XPO1JUNNFKB2 | |
| SCHEMBL79014 | 0.84 | NFKB1 (0.60) | NFKB1ATF1XPO1JUNNFKB2 | |
| SCHEMBL17315283 | 0.83 | NFKB1 (0.58) | NFKB1ATF1XPO1JUNNFKB2 | |
| SCHEMBL9564861 | 0.83 | NFKB1 (0.58) | NFKB1ATF1XPO1JUNNFKB2 | |
| SCHEMBL473934 | 0.82 | ATF1 (0.62) | NFKB1ATF1XPO1JUNNFKB2 | |
| SCHEMBL15290081 | 0.82 | NFKB1 (0.56) | NFKB1ATF1XPO1JUNNFKB2 | |
| SCHEMBL9564875 | 0.81 | NFKB1 (0.57) | NFKB1ATF1XPO1JUNNFKB2 | |
| SCHEMBL15273207 | 0.81 | NFKB1 (0.54) | NFKB1ATF1XPO1JUNNFKB2 | |
| SCHEMBL18081471 | 0.81 | NFKB1 (0.51) | NFKB1ATF1XPO1JUNNFKB2 | |
| SCHEMBL8398500 | 0.80 | NFKB1 (0.53) | NFKB1ATF1XPO1JUNNFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286948-A1 | HALOALKYLPYRIDYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR | HUYABIO INTERNATIONAL, LLC | 2023-09-14 | — | — | US | disclosed |
| US-20200138812-A1 | LIVER X RECEPTOR MODULATORS | VITAE PHARMACEUTICALS LLC (US) | 2020-05-07 | — | — | US | disclosed |
| US-20200138812-A1 | LIVER X RECEPTOR MODULATORS | VITAE PHARMACEUTICALS LLC (US) | 2020-05-07 | — | — | US | disclosed |
| US-20180133220-A1 | COMPOUNDS FOR USE IN TREATING ACUTE CORONARY SYNDROME AND RELATED CONDITIONS | VITAE PHARMACEUTICALS, LLC | 2018-05-17 | — | — | US | disclosed |
| US-20180133220-A1 | COMPOUNDS FOR USE IN TREATING ACUTE CORONARY SYNDROME AND RELATED CONDITIONS | VITAE PHARMACEUTICALS, LLC | 2018-05-17 | — | — | US | disclosed |
| US-20180133220-A1 | COMPOUNDS FOR USE IN TREATING ACUTE CORONARY SYNDROME AND RELATED CONDITIONS | VITAE PHARMACEUTICALS, LLC | 2018-05-17 | — | — | US | disclosed |
| US-20180117041-A1 | LIVER X RECEPTOR MODULATORS | VITAE PHARMACEUTICALS, INC. | 2018-05-03 | — | — | US | disclosed |
| US-20180117041-A1 | LIVER X RECEPTOR MODULATORS | VITAE PHARMACEUTICALS, INC. | 2018-05-03 | — | — | US | disclosed |
| US-20180117041-A1 | LIVER X RECEPTOR MODULATORS | VITAE PHARMACEUTICALS, INC. | 2018-05-03 | — | — | US | disclosed |
| US-20170231992-A1 | COMPOUNDS FOR USE IN TREATING ACUTE CORONARY SYNDROME AND RELATED CONDITIONS | VITAE PHARMACEUTICALS, INC. | 2017-08-17 | — | — | US | disclosed |
| WO-2013138568-A1 | LIVER X RECEPTION MODULATORS | VITAE PHARMACEUTICALS, INC. (US) | 2013-09-19 | — | — | WO | disclosed |
| WO-2013138568-A1 | LIVER X RECEPTION MODULATORS | VITAE PHARMACEUTICALS, INC. (US) | 2013-09-19 | — | — | WO | disclosed |
| US-20100041654-A1 | Pyrimidine Derivatives And Their Use As CB2 Modulators | EATHERTON ANDREW JOHN | 2010-02-18 | — | — | US | disclosed |
| US-20100041654-A1 | Pyrimidine Derivatives And Their Use As CB2 Modulators | EATHERTON ANDREW JOHN | 2010-02-18 | — | — | US | disclosed |
| US-7635701-B2 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LIMITED (GB) | 2009-12-22 | — | — | US | disclosed |
| US-20080132505-A1 | Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In Medicine | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
| US-5935966-A | COMPOUNDS THAT BLOCK THE ACTIVATION OF TRANSCRIPTION FACTORS THROUGH INHIBITION OF A FAMILY OF SPECIFIC KINASES, DECREASING PROINFLAMMATORY PROTEINS TO TREAT AUTOIMMUNE DISEASES AND AS GENERAL ANTIINFLAMMATORY AGENTS | SIGNAL PHARMACEUTICALS, INC. (US) | 1999-08-10 | — | — | US | disclosed |
| US-5852028-A | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions | SIGNAL PHARMACEUTICALS, INC. (US) | 1998-12-22 | — | — | US | disclosed |
| WO-1998038171-A1 | PYRIMIDINE CARBOXYLATES AND RELATED COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | SIGNAL PHARMACEUTICALS, INC. (US) | 1998-09-03 | — | — | WO | disclosed |
| WO-1997009325-A1 | PYRIMIDINE CARBOXYLATES AND RELATED COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | SIGNAL PHARMACEUTICALS, INC. (US) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180117041-A1 | LIVER X RECEPTOR MODULATORS | SLC10A1, NR1H4, NR1H2 | NFKB1 2853/4885ATF1 2247/4885XPO1 787/4885 |
| US-20170231992-A1 | COMPOUNDS FOR USE IN TREATING ACUTE CORONARY SYNDROME AND RELATED CONDITIONS | TNNI3, FABP3, TNNT2 | NFKB1 1156/4885ATF1 221/4885XPO1 4057/4885 |
| US-20230286948-A1 | HALOALKYLPYRIDYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR | WDR5, WDR1, WDR3 | NFKB1 2888/4885ATF1 551/4885XPO1 1133/4885 |
| US-20200138812-A1 | LIVER X RECEPTOR MODULATORS | SLC10A1, NR1H4, NR1H2 | NFKB1 2853/4885ATF1 2247/4885XPO1 787/4885 |
| US-20100041654-A1 | Pyrimidine Derivatives And Their Use As CB2 Modulators | CNR2, CNR1, P2RY2 | NFKB1 2616/4885ATF1 1190/4885XPO1 2382/4885 |
| US-20180133220-A1 | COMPOUNDS FOR USE IN TREATING ACUTE CORONARY SYNDROME AND RELATED CONDITIONS | TNNI3, FABP3, TNNT2 | NFKB1 1156/4885ATF1 221/4885XPO1 4057/4885 |
| US-20080132505-A1 | Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In Medicine | CNR2, CNR1, PDE4A | NFKB1 2991/4885ATF1 225/4885XPO1 3505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.